Trials / Withdrawn
WithdrawnNCT02537561
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
A Phase I Adaptive Design Trial of Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this proposed study the investigators will combine gemcitabine and cisplatin with talazoparib to determine the recommended Phase 2 dose (RP2D) of this combination regimen. After determination of the RP2D patients with lung cancer whose tumors carry molecular alterations in DNA repair pathway genes will be enrolled to an expansion cohort to determine anti-tumor efficacy. Tissue samples of patients with confirmed partial response, complete response, and non-responders will be obtained for whole exome, and transcriptome sequencing to characterize the genetic alterations associated with response to therapy.
Conditions
- Solid Tumors
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | |
| DRUG | Gemcitabine | |
| DRUG | Talazoparib |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-06-01
- Completion
- 2018-12-01
- First posted
- 2015-09-01
- Last updated
- 2016-02-11
Source: ClinicalTrials.gov record NCT02537561. Inclusion in this directory is not an endorsement.